ARA-290 (Cibinetide)

ARA-290, a non-erythropoietic peptide, represents a significant advancement in neuroprotective therapies, particularly for small fiber neuropathy. Engineered to activate the innate repair receptor (IRR) pathway, it offers tissue protection without stimulating red blood cells. Phase II clinical trials have shown efficacy in improving metabolic control and neuropathic symptoms among diabetic patients and individuals with sarcoidosis. With a promising safety profile and ongoing research into various therapeutic applications, ARA-290 is poised to make a considerable impact in neuropathy treatment.